Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 26% ± 13% | |
peripheral blood | 18 studies | 37% ± 12% | |
brain | 15 studies | 29% ± 15% | |
intestine | 7 studies | 20% ± 5% | |
liver | 6 studies | 31% ± 11% | |
kidney | 5 studies | 24% ± 7% | |
lymph node | 5 studies | 26% ± 4% | |
bone marrow | 4 studies | 36% ± 12% | |
eye | 4 studies | 25% ± 10% | |
heart | 4 studies | 20% ± 3% | |
adipose | 4 studies | 26% ± 6% | |
uterus | 3 studies | 33% ± 12% | |
breast | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5931.17 | 459 / 459 | 100% | 95.70 | 1118 / 1118 |
esophagus | 100% | 4607.41 | 1445 / 1445 | 100% | 119.14 | 183 / 183 |
lung | 100% | 5653.56 | 578 / 578 | 100% | 89.54 | 1155 / 1155 |
ovary | 100% | 4141.01 | 180 / 180 | 100% | 62.34 | 430 / 430 |
uterus | 100% | 4717.17 | 170 / 170 | 100% | 77.03 | 459 / 459 |
brain | 100% | 3349.69 | 2639 / 2642 | 100% | 74.51 | 705 / 705 |
intestine | 100% | 5055.08 | 966 / 966 | 100% | 65.20 | 526 / 527 |
bladder | 100% | 4872.14 | 21 / 21 | 100% | 65.78 | 503 / 504 |
prostate | 100% | 3983.70 | 245 / 245 | 100% | 58.06 | 501 / 502 |
thymus | 100% | 3876.83 | 652 / 653 | 100% | 51.54 | 602 / 605 |
kidney | 100% | 3375.47 | 89 / 89 | 99% | 59.32 | 895 / 901 |
stomach | 100% | 3400.62 | 359 / 359 | 99% | 69.50 | 284 / 286 |
skin | 100% | 5165.54 | 1809 / 1809 | 99% | 67.57 | 467 / 472 |
liver | 100% | 3596.21 | 226 / 226 | 99% | 37.79 | 401 / 406 |
pancreas | 97% | 2063.48 | 317 / 328 | 99% | 58.97 | 176 / 178 |
adrenal gland | 100% | 4016.05 | 258 / 258 | 93% | 28.49 | 214 / 230 |
adipose | 100% | 7018.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4899.34 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 97.42 | 29 / 29 |
muscle | 100% | 4614.06 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 6540.61 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 96.44 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 27.48 | 1 / 1 |
peripheral blood | 99% | 7194.41 | 922 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 3555.07 | 839 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 28.97 | 75 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_2001238 | Biological process | positive regulation of extrinsic apoptotic signaling pathway |
GO_0006469 | Biological process | negative regulation of protein kinase activity |
GO_2001271 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis |
GO_0034333 | Biological process | adherens junction assembly |
GO_0051493 | Biological process | regulation of cytoskeleton organization |
GO_0007165 | Biological process | signal transduction |
GO_0003300 | Biological process | cardiac muscle hypertrophy |
GO_0002223 | Biological process | stimulatory C-type lectin receptor signaling pathway |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0060996 | Biological process | dendritic spine development |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0070830 | Biological process | bicellular tight junction assembly |
GO_0006915 | Biological process | apoptotic process |
GO_0048010 | Biological process | vascular endothelial growth factor receptor signaling pathway |
GO_0016310 | Biological process | phosphorylation |
GO_0006468 | Biological process | protein phosphorylation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0043408 | Biological process | regulation of MAPK cascade |
GO_0150105 | Biological process | protein localization to cell-cell junction |
GO_0071407 | Biological process | cellular response to organic cyclic compound |
GO_0051497 | Biological process | negative regulation of stress fiber assembly |
GO_0050770 | Biological process | regulation of axonogenesis |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005911 | Cellular component | cell-cell junction |
GO_0005829 | Cellular component | cytosol |
GO_0014069 | Cellular component | postsynaptic density |
GO_0005737 | Cellular component | cytoplasm |
GO_0030141 | Cellular component | secretory granule |
GO_0005634 | Cellular component | nucleus |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0045296 | Molecular function | cadherin binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0031267 | Molecular function | small GTPase binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0030296 | Molecular function | protein tyrosine kinase activator activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PAK2 |
Protein name | p21 protein (Cdc42/Rac)-activated kinase 2 P21 (RAC1) activated kinase 2 Serine/threonine-protein kinase PAK 2 (EC 2.7.11.1) (Gamma-PAK) (PAK65) (S6/H4 kinase) (p21-activated kinase 2) (PAK-2) (p58) [Cleaved into: PAK-2p27 (p27); PAK-2p34 (p34) (C-t-PAK2)] |
Synonyms | |
Description | FUNCTION: Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell motility, cell cycle progression, apoptosis or proliferation . Acts as a downstream effector of the small GTPases CDC42 and RAC1 . Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues . Full-length PAK2 stimulates cell survival and cell growth . Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration . Phosphorylates JUN and plays an important role in EGF-induced cell proliferation . Phosphorylates many other substrates including histone H4 to promote assembly of H3.3 and H4 into nucleosomes, BAD, ribosomal protein S6, or MBP . Phosphorylates CASP7, thereby preventing its activity . Additionally, associates with ARHGEF7 and GIT1 to perform kinase-independent functions such as spindle orientation control during mitosis . On the other hand, apoptotic stimuli such as DNA damage lead to caspase-mediated cleavage of PAK2, generating PAK-2p34, an active p34 fragment that translocates to the nucleus and promotes cellular apoptosis involving the JNK signaling pathway . Caspase-activated PAK2 phosphorylates MKNK1 and reduces cellular translation . . |
Accessions | H7C1X3 ENST00000327134.7 Q13177 H9XFB4 ENST00000426668.1 |